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For the Women ' s Health Initiative Investigators

Background
Strategies for estrogen receptor (ER) -positive breast cancer risk reduction in postmenopausal women require screening of large populations to identify those with potential benefit. We evaluated and attempted to improve the performance of the Breast Cancer Risk Assessment Tool (i.e., the Gail model) for estimating invasive breast cancer risk by receptor status in postmenopausal women.
Methods
In The Women's Health Initiative cohort, breast cancer risk estimates from the Gail model and models incorporating additional or fewer risk factors and 5-year incidence of ER-positive and ER-negative invasive breast cancers were determined and compared by use of receiver operating characteristics and area under the curve (AUC) statistics. All statistical tests were two-sided.
Participants and Methods
Study Population
The WHI is a large multicomponent study designed to test three chronic disease risk reduction strategies and to examine risk factors for these conditions in postmenopausal women. Details of the implementation of both the observational study with 93 676 participants and the four randomized clinical trials with 68 132 participants that evaluated menopausal hormone therapy, a low-fat dietary intervention, and calcium -vitamin D supplementation have been published ( 8 ) . Briefly, women were recruited at 40 clinical centers in the United States largely through direct mailings ( 9 ) . Postmenopausal women, who were aged 50 -79 years and unlikely to move or die within 3 years, were eligible. Each randomized trial had additional eligibility requirements related to safety and the intervention under test. Potential participants who were not eligible or interested in the randomized trials entered the observational study. All clinical trials excluded women with a history of breast cancer and required that the baseline mammogram and clinical breast examination not be suspicious for breast cancer. Breast screening was not required for enrollment in the observational study enrollment. For these analyses, women with previous invasive breast cancer, previous noninvasive breast cancer, previous mastectomy, or less than 5 years follow-up were excluded, leaving 147 916 women who met all eligibility criteria.
All participants provided written informed consent. Human subjects committee approval at each participating institution was provided.
Data Collection
Participants provided data on demographics; medical, reproductive, and family medical histories; and lifestyle factors, such as smoking and alcohol use, and physical activity ( 10 ) . Menopausal hormone therapy use (i.e., use of estrogen alone or combined estrogen plus progestin) was ascertained through an interviewer-administered questionnaire.
The Gail model variables include age, ethnicity, age at menarche, age of the mother at the birth of her fi rst live child, number of fi rst-degree relatives with breast cancer (0, 1, or >1), number of previous breast biopsy examinations (0, 1, or >1), and the presence or absence of atypical hyperplasia in the biopsy specimen ( http://brca.nci.nih.gov/brc/questions.htm ). Calculations of 5-year risk estimates from the modifi ed Gail model for women in this report were made by the National Surgical Adjuvant Breast and Bowel Project statistical center by following their usual coding procedures on data from individual WHI participants, courtesy of Dr Joseph Costantino. Because historical information on atypical hyperplasia was not collected in the WHI, all women with previous breast biopsy examinations are coded as "unknown" for this last variable.
Follow-up and Breast Cancer Ascertainment
Breast cancer incidence and mammography use were updated annually (in the observational study) or semiannually (in the clinical trial) by mail or telephone questionnaires. Self-reported breast cancers were verified by centrally trained WHI physician adjudicators who reviewed pathology reports ( 11 ) . Final adjudication and coding were performed at the WHI Clinical Coordinating Center by use of the Surveillance, Epidemiology, and End Results Program ( 12 ) . Only the 3263 invasive breast cancers diagnosed within 5 years of enrollment and confirmed by central review were included as events, 713 in situ breast cancers were excluded from analyses, and 144 680 women with no invasive breast cancer were coded as control subjects. The 363 case patients with missing or borderline information on ER status were excluded from subgroup analyses.
Statistical Analyses
Risk of invasive breast cancer was initially assessed with the Gail model and coded as a four-level nominal variable with categories of no invasive breast cancer or invasive breast cancer that was considered as ER-positive and progesterone receptor (PR) -positive tumors, ER-positive and PR-negative tumors, or ER-negative tumors. There were too few ER-negative invasive cancers to subdivide this group by PR status. After initial receiver operating characteristic (ROC) analyses, the two ER-positive invasive breast cancer categories were combined resulting in three final nominal variables of no invasive breast cancer, ER-positive invasive breast cancer, and ER-negative invasive breast cancer.
To explore whether other models could predict ER-positive and ER-negative breast cancer with similar or improved accuracy, the data were divided into the distinct observational study and clinical trial cohorts. The prediction models that we investigated were the Gail model, which was tested in the clinical trial cohort, and three logistic regression models, which were trained on the observational study cohort and tested on the clinical trial cohort. The fi rst logistic regression model included the Gail model risk
CONTEXT AND CAVEATS
Prior knowledge
Because many postmenopausal women must be screened to identify a population who will benefit from tamoxifen treatment for breast cancer risk reduction, methods to rapidly identify such a population are needed.
Study design
Data from the observational study and the clinical trial cohorts of the Women's Health Initiative were used. Four prediction models were investigated, including the Gail model (tested in the clinical trial cohort) and three logistic regression models (trained on the observational study cohort and tested on the clinical trial cohort).
Contribution
A model with only three risk factors -age, breast cancer in firstdegree relatives, and previous breast biopsy examinationperformed nearly as well as the Gail model for the prediction of estrogen receptor (ER) -positive breast cancer.
Implications
The new model with fewer variables than the Gail model may be as effective at identifying women at high risk for ER-positive breast cancer who would benefit from risk reduction interventions. The discriminatory accuracy of each model was assessed and compared by use of the ROC curve (R version 2.3 and R library ROCR, R Development Core Team, http://www.R-project.org ) and the corresponding area under the curve (AUC). For models developed in the observational study cohort, the ROC and AUC were obtained by applying the models to the independent clinical trial cohort. ROC curves plot the true-positive rate (sensitivity) versus the false-positive rate (1 -specifi city) at a continuum of thresholds; a participant is predicted to have breast cancer if her estimated probability of breast cancer exceeds a particular threshold. An ROC curve that corresponds to a fair-coin toss classifi er (i.e., a nonpredictive model) is a straight line connecting the coordinates (0,0) to ( 1 , 1 ) and has an AUC of 0.50. An ROC curve that corresponds to a perfect classifi er is a pair of vertical and horizontal lines connecting the coordinates (0,0) to (0, 1 ) to ( 1 , 1 ) and has an AUC of 1.00.
Limitations
To aid in our understanding of the ROC analysis, a single multinomial logistic regression model (in SAS PROC LOGISTIC version 9.1; SAS Institute, Cary, NC) was used in the pooled clinical trial and observational study cohorts to examine whether risk factors were associated with ER-positive and ER-negative invasive breast cancer, separately and combined, and whether the associations differed by receptor status. Specifi cally, the estimated coefficients of the risk factors were allowed to vary by ER status. This model included the Gail model risk factors and the additional risk factors described above; to increase power, family history of breast cancer was recoded as 0 or 1 or more. All risk factors were included regardless of statistical signifi cance. Odds ratios (ORs), confi dence intervals (CIs), and P values for tests of main effects and for tests of heterogeneity between tumor types were based on Wald statistics. All statistical tests were two-sided.
To estimate absolute risks and prevent downward bias, missing receptor status was dealt with by a multiple imputation model. Because the main goal of this particular analysis is estimation, data from the WHI observational study and clinical trials were combined. Calibration was verifi ed by use of the Hosmer and Lemeshow goodness of fi t test ( 13 ) .
Results
Women in both the clinical trial and observational study cohorts were ethnically diverse and had a mean age of 63 years (range = 50 -79 years), with 21% being 70 years or older ( Table 1 ) . Serial mammography was common, with an average of 0.7 mammogram per year in both cohorts. Given the large sample size, tests for statistical significance between cohorts were highly statistically significant for nearly all characteristics. There appeared to be substantive differences between the cohorts in age, ethnicity or race, body mass index, family history, previous benign breast biopsy examination, and use of hormone therapy. Among 147 916 women eligible for these analyses, 3236 developed invasive breast cancer within 5 years. ER status was borderline or missing for 363 breast cancer patients, and 2412 ER-positive and 461 ER-negative invasive breast cancers were diagnosed.
The ROC curves for predicting invasive breast cancer by use of the Gail model 5-year risk probabilities for the 64 568 women in the WHI clinical trial produced an AUC of 0.58 (95% CI = 0.56 to 0.60). The AUC provided reasonable prediction of ER-positive and PR-positive tumors and ER-positive and PR-negative tumors (AUC = 0.60 for both). Given the similar ability to predict ERpositive and PR-positive tumors and ER-positive and PR-negative tumors, these categories were combined in subsequent modeling. For all ER-positive tumors, the usual Gail model threshold of 1.67%, used for defi ning increased risk, corresponds to approximately 50% sensitivity and 65% specifi city. For ER-negative tumors, the Gail model was comparable to a random process (AUC = 0.50, 95% CI = 0.45 to 0.54) ( Fig. 1 ) .
The accuracy of the Gail model estimated probabilities (calibration) for estimating the incidence of invasive breast cancer was assessed by comparing observed cases of breast cancer in the cohort with the number predicted by the Gail model (as the sums of the individual estimated Gail model probabilities of breast cancer). The Gail model 5-year risk estimate statistically signifi cantly underestimated the number of breast cancers diagnosed within 5 years by approximately 20% (3236 observed versus 2562 expected, P <.001) with the disparity concentrated among those with lower Gail model risk estimates ( ≤ 1.37% expected 5-year risk). The total Gail model estimate was more closely aligned with the number of ER-positive breast cancers observed ( Table 2 ) .
To better understand this difference in predictive performance between estimated breast cancer incidence from the Gail model and the observed incidence in the WHI cohort, we examined breast cancer risk factors by hormone receptor status (ER-positive tumors, ER-negative tumors, and cancer-free for 5 years) ( Table 3 ). In multinomial logistic regression analyses, the 5-year probability of ER-positive breast cancer in the entire cohort was statistically signifi cantly associated with age, ethnicity, family history of breast cancer, number of previous breast biopsy examinations, age at menopause, parity, age at fi rst birth, smoking status, alcohol use, and body mass index. African American women were at statistically signifi cantly lower risk of ER-positive disease than white women (OR = 0.68, 95% CI = 0.54 to 0.85).
Prior breast biopsy examination and body mass index were the only risk factors that were statistically signifi cantly associated with ER-negative disease. The smaller number of ER-negative tumors may have precluded detection of some associations; however, the data indicate a different pattern of association for most factors with ER-positive disease than with ER-negative disease. For ER-negative cancers, odds ratios for age, family history, age at menopause, greater parity, smoking, and alcohol use were all close to 1.0. The association between breast cancer risk and chronologic age ( P = .05), race or ethnicity ( P = .01), and age at menopause ( P = .04) differed statistically signifi cantly across ER disease subtypes ( Table  1 ). Age at menarche was not statistically signifi cantly associated with either ER-positive or ER-negative breast cancer.
To determine whether other models could improve Gail model performance for prediction of ER-positive breast cancer, the effects of the Gail model risk factors were reestimated in a logistic regression model that used the WHI observational study cohort as a training set, and the resulting model was applied to WHI clinical trial cohort as a test set. This approach differed from the original approach in that it did not explicitly account for competing risks. However, only 5.3% of women in the observational study and 4.7% of women in the clinical trial died or were lost to follow-up within 5 years of enrollment. Expanding this model to add parity, breastfeeding, smoking, alcohol, body mass index, physical activity, duration of previous estrogen-alone use, and duration of previous estrogen plus progestin use produced ROC curves in a similar pattern with only slight improvements in the AUC statistics ( Fig. 2 ) . By focusing on only ER-positive tumors, we simplifi ed the model to include only age, fi rst-degree relatives with breast cancer (coded as 0 or ≥ 1), and number of previous breast biopsy examinations (coded as 0, 1, or >1) and we obtained an AUC of 0.58 (95% CI = .56 to 0.60). The difference between the Gail model and the simplifi ed model at the estimated 1.8% probability threshold was small and not statistically significant (difference = 0.02, 95% CI = -0.04 to 0.08) ( Fig. 3 ) . The absolute risk prediction results for ER-positive invasive breast cancer from the simplifi ed model by age increments are shown in Table 4 . To prevent the downward bias of the predicted 5-year risk of ER-positive invasive breast cancers, missing receptor status was dealt with by multiple imputations. The imputation model included age, ethnicity, and age at menopause. These variables were chosen from Table 3 because these variables suggested differing risks by receptor status. ], age at menarche, and age at birth of fi rst child) plus age at menopause, parity, breast feeding, smoking, alcohol, body mass index, physical activity, duration or previous estrogen-alone use, and duration of previous estrogen plus progesterone use. ER = estrogen receptor; CI = confi dence interval. All women older than 55 years with either a previous biopsy examination or a fi rst-degree relative with breast cancer had a 5-year risk of invasive breast cancer that was greater than 1.8%. In an exploratory analysis, the same process was applied to African American participants in the clinical trial and observational study cohorts. For these African American women, women aged 60 years or older with a previous biopsy examination and a positive family history of breast cancer had a 5-year risk greater than 1.8% ( Table 4 ) .
Discussion
In a large cohort of postmenopausal women (50 -79 years of age at entry), the discriminatory performance of the Gail model was similar to that observed in previous studies ( 14 , 15 ) , but it underestimated the observed 5-year invasive breast cancer incidence by approximately 20%. Discriminatory performance and model calibration were somewhat better for estimating population-based risk of ER-positive breast cancers, but the performance of the Gail model for predicting ER-negative breast cancers was equivalent to chance alone. Incorporation of several additional risk factors provided only a small improvement in prediction. However, a simpler model that incorporated fewer variables was nearly as accurate as the Gail model in predicting ER-positive breast cancer risk and would be more accessible for routine and rapid prescreening in the prevention or routine care setting, in which breast cancer risk is only one measure among the many requiring assessment.
In our analyses, the association of putative risk factors with breast cancer prediction varied by ER status. For ER-positive breast cancers among postmenopausal women, the Gail model components of age, ethnicity, age of the mother at birth of her fi rst live child, number of fi rst-degree relatives with breast cancer, and number of prior breast biopsy examinations were statistically signifi cantly associated with breast cancer risk. Age at menarche was not associated with risk. Also associated with the risk of an ERpositive tumor were age at menopause, parity, and body mass index. In contrast, only prior breast biopsy examination and body mass index were statistically signifi cantly associated with the risk of ER-negative breast cancer, although the smaller number of patients with ER-negative breast cancer may have limited our ability to detect some associations, particularly for race or ethnicity.
Although the Gail model has been validated for predicting total breast cancer risk in several settings ( 14 , 15 ) , including both pre-and postmenopausal women, the utility of the Gail model for predicting ER-positive compared with ER-negative breast cancers in postmenopausal women has not been previously recognized to our knowledge. In these analyses, a woman's age, a Gail model component, was associated only with the risk of ER-positive breast cancer but not with the risk of ER-negative breast cancer. As a result, the Gail model appears to have the ability to differentially predict breast cancer risk by receptor subgroup in postmenopausal women.
Despite its well-documented predictive performance ( 14 , 15 ), the Gail model statistically signifi cantly underestimated breast cancer incidence in the WHI cohort of postmenopausal women. The initial four studies that validated the original Gail model included not only postmenopausal women but also some much younger premenopausal women ( 1 , 16 -18 ) , and two of these studies ( 17 , 18 ) entered women no older than 54 and 61 years at entry, respectively. In these studies, mammography was not prespecifi ed and was rarely used before the mid-1980s. Because tumors detected by mammography are more likely than those detected by other means to be ER-positive tumors than ER-negative tumors ( 19 ) and older women are substantially more likely than younger women to develop ER-positive tumors ( 20 ) , it is likely that these older studies did not optimally detect ER-positive disease. In contrast, the WHI cohort included only postmenopausal women who were 50 years or older, with a substantial number older than 70 years, and had comprehensively used mammography. In addition, a secular change in breast biopsy procedures had occurred, beginning in the early 1990s, away from open surgical biopsy examination to the common use of image-guided percutaneous core biopsy examinations, which are associated with less morbidity and a lower threshold for use ( 21 ) . As a result of these changes, the breast biopsy rate per 100 000 Medicare benefi ciaries increased by 43% between ( 22 ) . These factors likely contributed to a more comprehensive ascertainment of all patients with breast cancer in the WHI cohort, especially for those with ER-positive disease, and likely enhanced our ability to discriminate between the infl uences on ER-positive and ER-negative disease. Future development of breast cancer risk models, consequently, should consider premenopausal and postmenopausal women separately and segregate risk by hormone receptor status.
Other groups have examined the risk factors associated with breast cancer in hormone receptor subgroups ( 20 , 23 -25 ) . In a meta-analysis of observational studies, parity and age at fi rst child's birth were associated with ER-positive and PR-positive tumors but not with ER-negative and PR-negative breast cancers ( 22 ) . In another report ( 19 ) , statistically signifi cant heterogeneity among the four ER and PR categories was observed for some risk factors but not for prior breast biopsy examinations, family history of breast cancer, alcohol use, and height. Direct comparison with our analyses was precluded by differences in study populations, breast cancer receptor categories, and the risk factors examined.
Despite evaluation of multiple additional risk factors, we did not identify a model that would clearly improve the accuracy of risk prediction for ER-positive breast cancers over that of the Gail model. However, we did identify a simpler model with only three variables -age, family history of breast cancer in fi rst-degree relatives, and previous breast biopsy examination -which had predictive accuracy approaching that of the Gail model.
Although many women could potentially benefi t from tamoxifen use, there has been reluctance to incorporate Gail model breast cancer risk assessment in routine clinical practice ( 6 , 26 -28 ) . In one survey ( 6 ), only 11% of California primary care physicians had used the Gail model for risk assessment in the past year. In a recent national survey of primary care providers ( 29 ) , only 16% agreed that "it is easy to determine" who is eligible for breast cancer risk reduction strategies and only 25% had prescribed tamoxifen for risk reduction in the past year. As a result, development of new, simpler risk models is an identifi ed research priority ( 30 ) . The simplifi ed model described above provides a straightforward approach to initial screening for risk of ER-positive breast cancer in postmenopausal women and does not require computer use. Women who were 55 years or older with either a fi rst-degree relative with breast cancer or a previous breast biopsy have 5-year risk of 1.8% or higher (which is higher than the Gail model threshold of 1.67%).
In previous analyses of the WHI cohort ( 31 ), African American women were identifi ed as being at substantially lower risk for ERpositive breast cancer but at substantially higher risk for ER-negative, high-grade breast cancers with poor prognosis. These analyses suggest that African American women who were 60 years or older with a fi rst-degree relative with breast cancer and a previous breast biopsy examination may have a 5-year breast cancer risk of 1.8% or higher. Given the sample size in this subgroup, additional studies are needed to confi rm this fi nding. Because evaluation of the Gail model in multiethnic populations that include African American women have been preliminary ( 32 -33 ) or disappointing ( 34 ) , further model development in minority populations of African American and Hispanic women is a research priority.
The demonstration that the Gail model and our proposed simpler model can predict the risk of ER-positive breast cancer has several clinical implications. Although the selective estrogen receptor modulator (SERM) tamoxifen is approved by the Federal Drug Administration (FDA) for breast cancer risk reduction ( 35 ) , a large number of postmenopausal women must be screened to identify potential candidates. By one calculation, only one of 142 screened postmenopausal women who were 60 -79 years has a favorable balance for tamoxifen use ( 6 ) . The SERM raloxifene has recently been approved by the FDA for breast cancer risk reduction in postmenopausal women as well and has a somewhat more favorable side effect profi le ( 36 ) . The current Gail model or our simpler model could identify populations of postmenopausal women appropriate for further consideration for breast cancer risk reduction interventions. For interactions with individual women in the clinic, the limitations of any risk assessment estimate should be acknowledged and the risk or benefi t of any intervention should be carefully considered ( 3 , 26 ) .
Benign breast disease, a recognized breast cancer risk factor, may be able to integrate hormone exposures and breast tissue response that lead to mammographic breast alterations and indications for a biopsy examination. In the future, histologic subclassifi cation of benign breast disease (nonproliferative versus proliferative and the magnitude of lobular involution), which further differentiates breast cancer risk ( 37 -39 ) , may lead to more reliable risk estimation.
The strengths of this study include the prospective design, a large racially representative population that is well characterized for breast cancer risk factors and has serial assessment of mammography use, central adjudication of breast cancer pathology reports, and information on breast cancer hormone receptor status. In addition, the risk assessment models evaluated in this report were developed in one WHI population (the observational study cohort) and independently tested in a separate population (the clinical trial cohort), in which many of the risk assessment procedures and breast cancer outcomes were determined similarly.
Our study has several limitations. Information on atypical hyperplasia, a Gail model component, was not available in our cohort. However, the Gail model does allow for missing histologic subclassifi cation and that was how we coded the WHI data. We evaluated only one model and recognize other risk prediction models are in clinical use ( 29 ) . We selected the Gail model because it is the most commonly cited model, is the most frequently used by care providers in the United States, and is the basis for the FDA approved indication for use of tamoxifen for prevention.
Another study limitation is that reproductive hormone levels, mammogram breast density, and bone mineral density, which are strongly associated with breast cancer risk ( 40 -43 ), were not available for these analyses. However, analyses incorporating these risk factors have provided mixed results. Although estrogen levels have been commonly related to breast cancer ( 40 , 43 , 44 ) , in a randomized trial involving women at relatively high risk of breast cancer, estrogen and testosterone levels were not associated with either subsequent breast cancer risk or risk reduction by tamoxifen ( 45 ) . The addition of mammographic breast density has not improved ( 46 ) or only modestly improved ( 47 , 48 ) breast cancer prediction over the Gail model. To our knowledge, the infl uence of bone mineral density addition to Gail model prediction has not been reported. At present, therefore, the role of these three factors on the assessment of breast cancer risk in routine clinical practice remains to be determined.
In summary, we found that among postmenopausal women who receive regular mammographic examinations, the Gail model predicts ER-positive breast cancer risk at the population level but does not predict the risk of ER-negative tumors. A model incorporating only age, family history of breast cancer, and previous breast biopsy examinations provides a simpler approach for initial identifi cation of populations of postmenopausal women at elevated risk for ERpositive breast cancer who may benefi t by further evaluation for risk reduction interventions. Future attempts to improve breast cancer risk models should consider premenopausal and postmenopausal women separately and segregate risk by hormone receptor status.
